Merck’s Sneak Peek Into Its Drug Pricing May Not Be Enough to Satisfy Skeptics

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 3 February, 2017 by The TZ Newswire Staff

Merck’s Sneak Peek Into Its Drug Pricing May Not Be Enough to Satisfy Skeptics

Image source: Getty Images.

Welcome to 2017, where price transparency has become a top priority for drug developers following the targeting of Valeant Pharmaceuticals (NYSE: VRX) and Mylan (NASDAQ: MYL) for their pricing practices last year.

See also
- Next Article Economic Report: Service-sector growth strong but below forecast in January, ISM says
- Previous Article Economic Report: Factory orders jump 1.3% in December
Editorial Calender

February 2017

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28

« Jan Mar »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 3 February, 2017 by The TZ Newswire Staff

Merck’s Sneak Peek Into Its Drug Pricing May Not Be Enough to Satisfy Skeptics

See also

Editorial Calender

Recent Tags